CY1114403T1 - Φαρμακευτικη συνθεση, η οποια περιεχει γεσταγονα και/ή οιστρογονα και 5-μεθυλο(6s)-τετραϋδροφολικο - Google Patents

Φαρμακευτικη συνθεση, η οποια περιεχει γεσταγονα και/ή οιστρογονα και 5-μεθυλο(6s)-τετραϋδροφολικο

Info

Publication number
CY1114403T1
CY1114403T1 CY20121100689T CY121100689T CY1114403T1 CY 1114403 T1 CY1114403 T1 CY 1114403T1 CY 20121100689 T CY20121100689 T CY 20121100689T CY 121100689 T CY121100689 T CY 121100689T CY 1114403 T1 CY1114403 T1 CY 1114403T1
Authority
CY
Cyprus
Prior art keywords
methyl
lack
folate
congenital
tetrahydrofolate
Prior art date
Application number
CY20121100689T
Other languages
English (en)
Inventor
Kai Strothmann
Gavin Smith
Kristina King
Rudolf Moser
Klaus Pietrzik
Original Assignee
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37396913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114403(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102005023301A external-priority patent/DE102005023301B4/de
Priority claimed from DE102006016285A external-priority patent/DE102006016285A1/de
Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh
Publication of CY1114403T1 publication Critical patent/CY1114403T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Η προκειμένη εφεύρεση αναφέρεται σε μια φαρμακευτική σύνθεση, η οποία περιέχει γεσταγόνα, κατά προτίμηση δροσπιρενόνη, οιστρογόνα, κατά προτίμηση αιθινυλ-οιστραδιόλη, και 5-μεθυλο-(6S)-τετραϋδροφολικό. Η σύνθεση αυτή θα μπορεί να χρησιμοποιηθεί ως στοματικό αντισυλληπτικό και θα προλαμβάνει παθήσεις των γυναικών που το χρησιμοποιούν που οφείλονται σε έλλειψη φολικού, ιδιαίτερα καρδιαγγειακές παθήσεις και συγγενείς διαμαρτίες διάπλασης οφειλόμενες σε έλλειψη φολικού μετά από τη σύλληψη του εμβρύου, όπως για παράδειγμα ανωμαλίες του νευρικού σωλήνα, ανωμαλίες της βαλβίδας της κοιλίας της καρδιάς, ανωμαλίες των ουροποιογεννητικών οργάνων, καθώς και σχιστίες των χειλών, της γνάθου και της υπερώας, χωρίς να συγκαλύπτει τα συμπτώματα μιας έλλειψης βιταμίνης Β12, και ταυτόχρονα ακόμα και σε περίπτωση ενός ομοζυγωτού ή ετεροζυγωτού πολυμορφισμού της μεθυλενοτετραϋδροφυλλικής ρεδουκτάσης θα διευκολύνει την απεριόριστη χρηστικότητα του φολικού συστατικού 5-μεθυλο-(6S)-τετραϋδροφολικό από τον οργανισμό και επομένως θα διευκολύνει και τη βιολογική του δράση για την αποφυγή των προαναφερόμενων συγγενών διαμαρτιών διάπλασης που οφείλονται στην έλλειψη φολικού. Επιπλέον θα διατηρεί μια προστατευτική δράση μεγαλύτερης διάρκειας μετά τη διακοπή λήψης του αντισυλληπτικού.
CY20121100689T 2005-05-13 2012-08-02 Φαρμακευτικη συνθεση, η οποια περιεχει γεσταγονα και/ή οιστρογονα και 5-μεθυλο(6s)-τετραϋδροφολικο CY1114403T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005023301A DE102005023301B4 (de) 2005-05-13 2005-05-13 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
DE102006016285A DE102006016285A1 (de) 2006-04-03 2006-04-03 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
EP09075120.7A EP2116249B2 (de) 2005-05-13 2006-05-15 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat

Publications (1)

Publication Number Publication Date
CY1114403T1 true CY1114403T1 (el) 2016-08-31

Family

ID=37396913

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091100804T CY1109261T1 (el) 2005-05-13 2009-07-28 Φαρμακευτικη συνθεση, η οποια περιεχει γεσταγονα και / ή οιστρογονα και 5-μεθυλο-(6s)-τετραϋδροφολικο
CY20121100689T CY1114403T1 (el) 2005-05-13 2012-08-02 Φαρμακευτικη συνθεση, η οποια περιεχει γεσταγονα και/ή οιστρογονα και 5-μεθυλο(6s)-τετραϋδροφολικο

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20091100804T CY1109261T1 (el) 2005-05-13 2009-07-28 Φαρμακευτικη συνθεση, η οποια περιεχει γεσταγονα και / ή οιστρογονα και 5-μεθυλο-(6s)-τετραϋδροφολικο

Country Status (38)

Country Link
US (2) US20080160004A1 (el)
EP (3) EP2116249B2 (el)
JP (2) JP2008540482A (el)
KR (2) KR101598735B1 (el)
CN (2) CN101954083A (el)
AR (1) AR054123A1 (el)
AT (2) ATE429917T1 (el)
AU (1) AU2006245921A1 (el)
BR (1) BRPI0611443B8 (el)
CA (1) CA2608639C (el)
CL (2) CL2009002187A1 (el)
CR (1) CR9531A (el)
CY (2) CY1109261T1 (el)
DE (1) DE502006003617D1 (el)
DK (2) DK2116249T3 (el)
DO (1) DOP2006000110A (el)
EA (2) EA014664B1 (el)
EC (1) ECSP078001A (el)
ES (2) ES2325600T3 (el)
GT (1) GT200600200A (el)
HK (1) HK1118729A1 (el)
HR (1) HRP20090418T1 (el)
IL (1) IL187340A (el)
MA (1) MA29448B1 (el)
MY (1) MY147362A (el)
NO (1) NO345807B1 (el)
PE (1) PE20061415A1 (el)
PL (2) PL2116249T3 (el)
PT (2) PT2116249E (el)
RS (2) RS52651B (el)
SG (1) SG169973A1 (el)
SI (2) SI1888077T1 (el)
SV (1) SV2008002527A (el)
TN (1) TNSN07418A1 (el)
TW (1) TWI380820B (el)
UY (1) UY29527A1 (el)
WO (1) WO2006120035A2 (el)
ZA (1) ZA200710811B (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
EP1891959A1 (de) * 2006-08-14 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
DE112007001600A5 (de) * 2006-07-06 2009-04-30 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
PE20090805A1 (es) * 2007-04-05 2009-07-25 Bayer Schering Pharma Ag COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL
EA201070715A1 (ru) * 2007-12-20 2011-02-28 Тева Вимен'С Хелс, Инк. Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции
WO2009112232A2 (en) * 2008-03-10 2009-09-17 Vladimir Hanes New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
WO2009112231A2 (en) * 2008-03-10 2009-09-17 Schuermann Rolf New drospirenone/17beta-estradil regimen, pharmaceutical combination product and kit for performing this regimen
BR112012026115B1 (pt) 2010-04-15 2019-12-24 Bayer Ip Gmbh forma de dosagem oral sólida, seu uso, e unidade de acondicionamento
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP2617422A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate
EP2781214A1 (en) 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
CN104490887A (zh) * 2014-09-04 2015-04-08 连云港金康和信药业有限公司 (6s)-5-甲基-四氢叶酸钙盐的稳定药物组合物
NO3106148T3 (el) 2015-06-18 2018-08-11
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
WO2016203009A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN106336444A (zh) * 2016-08-23 2017-01-18 国家卫生计生委科学技术研究所 一种新晶型炔雌醇
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK174724B1 (da) * 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
ZA939565B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
US6083528A (en) * 1995-09-28 2000-07-04 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
AU7522896A (en) * 1995-10-27 1997-05-15 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
CA2243981C (en) 1996-01-31 2005-09-06 South Alabama Medical Science Foundation Food and vitamin preparations containing the natural isomer of reduced folates
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
UA68365C2 (en) * 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
TR200002995T2 (tr) * 1998-04-17 2001-01-22 Ortho-Mcneil Pharmaceutical,Inc. Folik asit ihtiva eden farmasötik bileşimler, bununla ilgili yöntemler ve uygulama sistemleri
CA2348693C (en) * 1998-10-19 2008-07-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid
US7014865B1 (en) 1998-10-19 2006-03-21 Merck Patent Gmbh Natural formulation for the treatment and prevention of depression, containing St. John's Wort and derivatives of dihydro- and tetrahydrofolic acid
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
HU225779B1 (en) 1999-07-28 2007-08-28 Chinoin Gyogyszer Es Vegyeszet Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
NZ517845A (en) 1999-08-31 2004-12-24 Schering Ag Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US6479545B1 (en) 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
DE10022510A1 (de) * 2000-05-10 2001-11-15 Basf Ag Zusammensetzungen enthaltend Folsäure und reduziertes Folat
US20020094970A1 (en) * 2000-12-14 2002-07-18 Ronenn Roubenoff Compositions and methods for treating an arthritic condition
US20030045510A1 (en) * 2000-12-15 2003-03-06 Schloss Caroline Maxine Estrogen-plus
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
US20040220118A1 (en) * 2001-02-02 2004-11-04 Bland Jeffrey S. Medical composition for balancing bodily processes
US20060034954A1 (en) * 2001-02-02 2006-02-16 Bland Jeffrey S Medical composition for balancing bodily processes
ES2274107T3 (es) * 2002-02-21 2007-05-16 Bayer Schering Pharma Ag Composiciones farmaceuticas comprendiendo uno o mas esterioides, uno o mas componentes de tetrahidrofolato vitamina b12.
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.

Also Published As

Publication number Publication date
US20080160004A1 (en) 2008-07-03
ES2325600T3 (es) 2009-09-09
SG169973A1 (en) 2011-04-29
JP2008540482A (ja) 2008-11-20
EA028530B1 (ru) 2017-11-30
PL2116249T3 (pl) 2013-06-28
EP1888077A2 (de) 2008-02-20
HRP20090418T1 (en) 2009-09-30
JP5883810B2 (ja) 2016-03-15
ATE555791T1 (de) 2012-05-15
EP2116249B1 (de) 2012-05-02
HK1118729A1 (en) 2009-02-20
EP2116249B2 (de) 2023-04-05
IL187340A0 (en) 2011-08-01
PT1888077E (pt) 2009-07-20
CN101198332A (zh) 2008-06-11
CN101954083A (zh) 2011-01-26
KR101598735B1 (ko) 2016-03-02
SI1888077T1 (sl) 2009-10-31
EP2298307A1 (de) 2011-03-23
WO2006120035A3 (de) 2007-02-15
MY147362A (en) 2012-11-30
MA29448B1 (fr) 2008-05-02
CN101198332B (zh) 2012-07-18
KR20080028369A (ko) 2008-03-31
BRPI0611443B8 (pt) 2021-05-25
DE502006003617D1 (de) 2009-06-10
JP2013166753A (ja) 2013-08-29
IL187340A (en) 2015-03-31
BRPI0611443A2 (pt) 2010-09-08
WO2006120035A2 (de) 2006-11-16
US20160095860A1 (en) 2016-04-07
EA200702349A1 (ru) 2008-04-28
CY1109261T1 (el) 2014-07-02
RS50972B (sr) 2010-10-31
ATE429917T1 (de) 2009-05-15
ES2387525T3 (es) 2012-09-25
NO345807B1 (no) 2021-08-16
PT2116249E (pt) 2012-08-07
KR20140069175A (ko) 2014-06-09
CR9531A (es) 2008-02-21
NO20076408L (no) 2008-02-12
CA2608639A1 (en) 2006-11-16
TWI380820B (zh) 2013-01-01
TNSN07418A1 (en) 2009-03-17
DK2116249T3 (da) 2012-08-20
PE20061415A1 (es) 2007-01-26
US10463666B2 (en) 2019-11-05
SV2008002527A (es) 2008-03-27
CL2009002187A1 (es) 2010-10-01
ECSP078001A (es) 2008-01-23
PL1888077T3 (pl) 2009-12-31
SI2116249T1 (sl) 2013-02-28
EP2116249A1 (de) 2009-11-11
DK1888077T3 (da) 2009-08-17
EA014664B1 (ru) 2010-12-30
AR054123A1 (es) 2007-06-06
DOP2006000110A (es) 2012-06-15
RS52651B (en) 2013-06-28
GT200600200A (es) 2007-03-23
EP1888077B1 (de) 2009-04-29
CL2010000989A1 (es) 2011-02-18
TW200711651A (en) 2007-04-01
EA200901393A1 (ru) 2010-02-26
ZA200710811B (en) 2012-06-27
AU2006245921A1 (en) 2006-11-16
CA2608639C (en) 2013-04-30
BRPI0611443B1 (pt) 2020-07-21
UY29527A1 (es) 2006-12-29

Similar Documents

Publication Publication Date Title
CY1114403T1 (el) Φαρμακευτικη συνθεση, η οποια περιεχει γεσταγονα και/ή οιστρογονα και 5-μεθυλο(6s)-τετραϋδροφολικο
AR106561A2 (es) Composición farmacéutica que contiene un ácido tetrahidrofólico
MX2008000087A (es) Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
NZ595393A (en) Methods and compositions for improving pregnancy outcome
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
EP1906968A4 (en) NEW SCHEMES FOR ORAL MONOPHASIC CONTRAZEPTIVA
ES2438734T3 (es) Anticonceptivo que contiene ácido fólico
CL2007001961A1 (es) Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo.
AU2006342119A8 (en) Soluble human M-CSF receptor and uses thereof
ES2432378T3 (es) Forma de administración para la anticoncepción hormonal
AR049196A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
PE20090805A1 (es) COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL
JOP20100287B1 (ar) مركب دوائي يشتمل على بروجستينات واستروجينات، احدهما او كلاهما، و5 - مثيل - (6s)- رابع هايدروفولات
MA38465A1 (fr) Forme posologique de l'antagoniste du récepteur de la progestérone
CY1120971T1 (el) Θεραπεια της ατροφιας του κολπου σε γυναικες με κινδυνο εμφανισης καρδιαγγειακων παθησεων
CU20070252A7 (es) Composición farmacéutica que contiene drospirenona, etinilestradiol y la sal de calcio del ácido 5-metil-(6s)-tetrahidrofólico
DE602006002328D1 (de) Polysubstituierte 1,1-pyridinyloxycyclopropanamine Derivate, Verfahren zu ihrer Herstellung und die enthaltenden pharmazeutischen Zusammensetzungen
TH105386B (th) องค์ประกอบทางเภสัชกรรมซึ่งประกอบรวมด้วยโปรเจสโตเจน และ/หรือ เอสโตรเจน และ 5-เมธิล-(6s)-เททระไฮโดรโฟเลต
TH105386A (th) องค์ประกอบทางเภสัชกรรมซึ่งประกอบรวมด้วยโปรเจสโตเจน และ/หรือ เอสโตรเจน และ 5-เมธิล-(6s)-เททระไฮโดรโฟเลต
TH94755B (th) สารผสมทางเภสัชกรรมเพื่อการคุมกำเนิด และ สำหรับลดความเสี่ยงความผิดปกติที่เป็นมาแต่กำเนิด